Johnson & Johnson $JNJ Shares Sold by Venture Visionary Partners LLC

Venture Visionary Partners LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 65,328 shares of the company’s stock after selling 2,412 shares during the period. Venture Visionary Partners LLC’s holdings in Johnson & Johnson were worth $12,113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $27,000. Semmax Financial Advisors Inc. lifted its holdings in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the last quarter. GFG Capital LLC acquired a new position in Johnson & Johnson in the second quarter valued at approximately $35,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson during the first quarter valued at approximately $48,000. Finally, Vermillion & White Wealth Management Group LLC raised its position in shares of Johnson & Johnson by 66.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock worth $57,000 after purchasing an additional 150 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ stock opened at $209.33 on Wednesday. The company has a market capitalization of $504.32 billion, a P/E ratio of 20.21, a PEG ratio of 2.39 and a beta of 0.36. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The company has a 50-day simple moving average of $197.02 and a 200 day simple moving average of $178.23. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $215.18.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Analysts Set New Price Targets

JNJ has been the subject of a number of analyst reports. Raymond James Financial boosted their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a report on Monday, October 20th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Finally, Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $208.35.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.